Company News-宜明昂科英文

Company News

Company News

Company News

ImmuneOnco’s Subcutaneous IMM2510S IND Application Accepted, Pioneering a New Era of Bispecific Drug Delivery

This milestone marks a critical step in the formulation optimization of the IMM2510 program, promising a superior treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.

ImmuneOnco Subsidiary ImmuneCare Biopharmaceuticals Completes Enrollment for IMC-003 MAD Study, Marking New Phase in PAH Drug Development

This milestone represents a solid step forward in the clinical development of IMC-003, laying a crucial foundation for evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics under multiple dosing regimens, and holding promise to bring new hope to patients suffering from PAH.

ImmuneOnco Initiates Phase III Trial of Amulirafusp Alfa (IMM0306) in Relapsed/Refractory Follicular Lymphoma

This pivotal trial, evaluating amulirafusp alfa in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL), marks the official entry of the therapy into the pivotal clinical stage.

ImmuneOnco Announces Phase III Study of Timdarpacept (IMM01) in CMML Reaches Interim Analysis Milestone with 133 Subjects Enrolled

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces That the Phase III Study of timdarpacept (IMM01) for CMML Has Completed Enrollment of 133 Subjects, Achieving the Milestone of 132 Subjects for Interim Analysis

ImmuneOnco Receives NMPA Approval for Phase II Trial of Amulirafusp Alfa (IMM0306) in Primary Membranous Nephropathy

ImmuneOnco’s Amulirafusp Alfa (IMM0306) Granted NMPA Approval for Phase II Study in Primary Membranous Nephropathy

ImmuneOnco’s IMM0306S Subcutaneous Formulation for SLE Approved by NMPA; Autoimmune Pipeline Expands

This milestone marks a significant breakthrough in ImmuneOnco’s innovative drug development within the autoimmune disease sector.

总计 109 1 234 5 6 7 8...18 19